X4 Pharmaceuticals, Inc (XFOR) stock
XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.00+0.04 (+1.35%)
Close on Nov 20, 2026Market cap $297.44MP/E –Yield –
X4 Pharmaceuticals gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
X4 Pharmaceuticals's gross profit for the twelve months ending Sep 30, 2026 was $6.81M, up 136060.0% year over year. For fiscal 2025 it was $743.00K, down 58.8% from the year before.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $743.00K | -58.8% |
| FY2024 | Dec 31, 2024 | $1.80M | – |
| FY2023 | Dec 31, 2023 | $0 | – |
| FY2022 | Dec 31, 2022 | $0 | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.29M | +83.1% |
| Q2 FY2026 | Jun 30, 2026 | $783.00K | -43.0% |
| Q1 FY2026 | Mar 31, 2026 | $1.90M | – |
| Q4 FY2025 | Dec 31, 2025 | $1.84M | +53.3% |
| Q3 FY2025 | Sep 30, 2025 | $1.25M | +275.1% |
| Q2 FY2025 | Jun 30, 2025 | $1.37M | +365.8% |
| Q1 FY2025 | Mar 31, 2025 | -$3.82M | – |
| Q4 FY2024 | Dec 31, 2024 | $1.20M | – |
| Q3 FY2024 | Sep 30, 2024 | $333.00K | – |
| Q2 FY2024 | Jun 30, 2024 | $295.00K | – |
| Q1 FY2024 | Mar 31, 2024 | $0 | – |
| Q2 FY2023 | Jun 30, 2023 | $0 | – |
See a number that looks wrong?